Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer

The optimal duration of first-line immunotherapy for advanced non-small cell lung cancer (aNSCLC) is not known. A population-based retrospective cohort study of patients on frontline immunotherapy-based treatment, found that only approximately 1 in 5 patients discontinued immunotherapy at 2 years in the absence of progression. On adjusted analysis, there was no statistically significant difference in overall survival between patients who received a fixed duration of therapy for 2 years versus those who continued treatment indefinitely. The author conclude that for patients who are progression-free on immunotherapy for aNSCLC, it is reasonable to stop therapy at 2 years, rather than continuing indefinitely.